Search research articles
Contact Us
Filters
Showing results (81-90 of 96) with videos related to
Page
of 10
Sort By:
Genomics Data
|
October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients
B Haibe-Kains, C Desmedt, A Di Leo, et al.
Science Translational Medicine
|
April 19, 2019
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Gloria V Echeverria, Zhongqi Ge, Sahil Seth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Seminars in Cancer Biology
|
July 11, 2018
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F Klauschen, K-R Müller, A Binder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et al
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
L Du, C Yau, L Brown-Swigart, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
M Marczyk, A Mrukwa, C Yau, et al.
Breast Cancer Research : BCR
|
May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer
Sahil Seth, Clinton Yam, Lei Huo, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 96) with videos related to
Sort By:
Page
of 10
Genomics Data
|
October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients
B Haibe-Kains, C Desmedt, A Di Leo, et al.
Science Translational Medicine
|
April 19, 2019
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Gloria V Echeverria, Zhongqi Ge, Sahil Seth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Seminars in Cancer Biology
|
July 11, 2018
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
F Klauschen, K-R Müller, A Binder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et al
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
L Du, C Yau, L Brown-Swigart, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
M Marczyk, A Mrukwa, C Yau, et al.
Breast Cancer Research : BCR
|
May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer
Sahil Seth, Clinton Yam, Lei Huo, et al.
Page
of 10